Skip to main content
HairCited

デュタステリド 男性型・女性型脱毛症(AGA)

A

合計12,060名の参加者を対象とした43件の研究(メタアナリシス7件、RCT 1件を含む)に基づく。43件中34件の研究で肯定的な効果が示されている。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Ddutasteride\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

Dutasteride has strong scientific support for androgenetic alopecia and research suggests it may be more effective than finasteride, though it should be used under medical supervision due to potential side effects.

  • 34 out of 43 studies show positive effects across 12,060 participants
  • Multiple meta-analyses consistently support dutasteride's effectiveness for pattern hair loss
  • Blocks both type I and type II 5-alpha reductase enzymes, potentially offering broader DHT reduction than finasteride
  • Available in both oral and topical formulations, with topical forms being actively researched

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 効果: None None

対象集団: women with androgenetic alopecia (female pattern hair loss)

Randomized Controlled Trial n=139 24 weeks Double-blind
Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, …
Dose: 0.2 mg dutasteride daily vs: Placebo; 0.5 mg dutasteride daily Outcome: Change in hair count at vertex from baseline 効果: 21.53 vs 5.96 hair count increase 0.0072

対象集団: Men with androgenetic alopecia

Controlled Clinical Trial n=8 12 weeks Single-blind
Dutasteride Infusion in Male Androgenetic Alopecia Using a Novel Drug Delivery Technique: MMP®.
Dose: 3 sessions of dutasteride microinfusion (monthly) vs: Saline solution placebo via MMP Outcome: Clinical assessment and patient self-assessment 効果: None None

対象集団: Adult males with androgenetic alopecia

Other n=20 8 weeks Open-label
Efficacy of Skin Patting and Iontophoresis with Dutasteride Gel in Male and Menopausal Female Androgenetic …
Dose: 4 monthly sessions of SPi + iontophoresis vs: Baseline (pre-post design, no control) Outcome: Hair density, shaft diameter, pull test at 8 … 効果: None <0.001 (density, diam, pull)

対象集団: 10 males + 10 postmenopausal females with resistant AGA

Review
Efficacy and safety of dutasteride in the treatment of alopecia: a comprehensive review.
Dose: Dutasteride (oral, various doses) vs: Placebo 効果: None None
Review
Male and female pattern hair loss.
Dose: None vs: Placebo 効果: None None

Key Statistics

99

研究数

19921

参加者数

Positive

A

グレード

Referenced Papers

Journal of cosmetic … 2025 3 件の引用
Australian prescriber 2025 2 件の引用
Journal of cutaneous … 2025 2 件の引用
Journal of clinical … 2025 1 件の引用
Annals of dermatology 2025
Dermatology (Basel, Switzerland) 2024 14 件の引用
Journal of cosmetic … 2024 11 件の引用
Facial plastic surgery … 2024 8 件の引用
American journal of … 2023 41 件の引用
Dermatology and therapy 2023 23 件の引用
Fertility and sterility 2020 94 件の引用
Neurobiology of stress 2020 72 件の引用
General and comparative … 2020 37 件の引用
Facial plastic surgery … 2020 15 件の引用
Alternative therapies in … 2020 11 件の引用
Archivos espanoles de … 2020 1 件の引用
Journal of the … 2019 55 件の引用
The aging male … 2019 19 件の引用
Assay and drug … 2019 19 件の引用
Expert opinion on … 2018 38 件の引用
Current clinical pharmacology 2017 62 件の引用
International journal of … 2017 45 件の引用
Actas dermo-sifiliograficas 2017 17 件の引用
The Cochrane database … 2016 18 件の引用
Indian journal of … 2016 8 件の引用
Current problems in … 2015 8 件の引用
Expert opinion on … 2014 57 件の引用
Current opinion in … 2014 43 件の引用
Dermatologic clinics 2013 78 件の引用
Journal of cosmetic … 2013 62 件の引用
Facial plastic surgery … 2013 16 件の引用
International journal of … 2013
Skin therapy letter 2012 100 件の引用
Expert opinion on … 2010 264 件の引用
Current opinion in … 2009 54 件の引用
Seminars in cutaneous … 2009 4 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

hairloss:
0.5 mg/day (off-label)

上限量: 0.5 mg/day

研究で検討された用量

用量 期間 効果 N
None -- Neutral --
0.2 mg dutasteride daily 24 weeks Positive 139
3 sessions of dutasteride microinfusion (monthly) 12 weeks Positive 8
4 monthly sessions of SPi + iontophoresis 8 weeks Positive 20
Dutasteride (oral, various doses) -- Positive --
None -- Positive --
None -- Positive --
None -- Positive --

推奨摂取タイミング: Once daily at the same time, with or without food; prescription required

Safety & Side Effects

報告されている副作用

  • Decreased libido (more common than finasteride)
  • Erectile dysfunction
  • Ejaculation disorders
  • Gynecomastia (breast tissue growth)
  • Very long half-life (~5 weeks) means slow side effect resolution

既知の相互作用

  • CYP3A4 inhibitors (ketoconazole, ritonavir) may increase dutasteride levels
  • May affect PSA levels (reduces by ~50%)
  • Contraindicated in pregnancy (Category X teratogen)

耐容上限摂取量: 0.5 mg/day

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does デュタステリド help with 男性型・女性型脱毛症(AGA)?
Based on 99 studies with 19,921 participants, there is strong evidence from multiple clinical trials that デュタステリド may support 男性型・女性型脱毛症(AGA) management. Our evidence grade is A (Strong Evidence).
How much デュタステリド should I take for 男性型・女性型脱毛症(AGA)?
Studies have used various dosages. A commonly studied range is 0.5 mg/day (off-label). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of デュタステリド?
Reported side effects may include Decreased libido (more common than finasteride), Erectile dysfunction, Ejaculation disorders, Gynecomastia (breast tissue growth). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for デュタステリド and 男性型・女性型脱毛症(AGA)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 99 peer-reviewed studies with 19,921 total participants. The overall direction of effect is positive.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。